Clinical effect of Astragalus granule of different dosages on quality of life in patients with chronic heart failure
- 136 Downloads
To explore the dose-effect relationship of Astragalus granule (AG) on improving the quality of life (QOL) of the patients with chronic heart failure (CHF).
Ninety CHF patients of Fei (肺)-qi-deficiency and/or Xin (心)-Shen (肾) yang-deficiency syndromes were equally randomized divided with a random number table into three groups; they received the high (7.5 g), moderate (4.5 g), and low dosage (2.25 g) of AG orally taken twice a day, respectively, and 4 mg of perindopril tablet once a day for 30 successive days. The heart function grade, patients’ left ventricular ejection fraction (LVEF) and walking distance in 6 min (6mWD) were measured before and after treatment, and the patients’ QOL was scored by the Minnesota Questionnaire for QOL evaluation in the patients with CHF at the same time.
The heart function grades of all the three groups after treatment were improved compared with those before treatment, but the improvements in high-dose group and moderate dose group were better than that in the low dose group (P<0.05). LVEFs were increased significantly in all the three groups, but the improvements in the high-dose group (59.42%±7.50%) and moderate dose group (61.98%±6.82%) were better than that in the low dose group (51.45%±6.80%, P<0.01); the 6mWDs in the all groups were also significantly increased (P<0.01), up to 419.80±36.23 m, 387.15±34.13 m, and 317.69±39.97 m, respectively; and Minnesota scores in them were lowered to 29.59±4.69 scores, 35.74±5.89 scores, and 42.78±6.06 scores, respectively; comparisons in aspects on 6mWD and Minnesota score showed that the effectiveness with high dose is the most effective, moderate dose as the second, and low dose as the lowest (P<0.01).
AG was sufficient to display an optimal effect on improving heart contraction at the moderate dose. In aspects of improving the QOL of CHF patients, the effectiveness of AG showed a dose-dependent trend. It should be applied discriminatively depending on the actual condition of patients and the aim of treatment in clinic.
Keywordsastragalus heat failure heart function quality of life dose-effect relationship
Unable to display preview. Download preview PDF.
- 1.Wu XS. Progression in diagnosis and treatment of chronic heart failure. Chin J Pract Intern Med (Chin) 2006;26:408–410.Google Scholar
- 2.China Society of Cardiovascular Diseases, Chinese Medical Association, the Editorial Board of Chinese Journal of Cardiology. Guidlines for the diagnosis and treatment of chronic heart failure. Chin J Cardiol (Chin) 2007;35:1076–1095.Google Scholar
- 3.Zheng XY, ed. Guiding principle of clinical research on new drugs of traditional chinese medicine. 1st ed. Beijing: China Medical Science and Technology Press;2002:77–80.Google Scholar
- 4.Li DP, Chen Q, Yi L, Zhao Y, Liao H, Xu J. Eeffects of Yiqi Huoxue method on cardiac function in patients with congestive heart failure. Chin J Integr Tradit West Med (Chin) 2006;26:552–554.Google Scholar
- 8.Liu ZG, Xiong ZM, Yu XY. Effect of Astragalus Injection on immune function in patients with congestive heart failure. Chin J Integr Tradit West Med (Chin) 2003;23:351–353.Google Scholar